Clinical Trial Update: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa [Phase 2, Phase 3]

View source ↗

Summary

Pivotal Phase 2b/3 trial in South Africa evaluates the safety and efficacy of an ALVAC-based HIV vaccine with bivalent gp120 and MF59 adjuvant; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ALVAC/Bivalent gp120/MF59 HIV Vaccine (ALVAC-based HIV vaccine with bivalent gp120 and MF59 adjuvant)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-02-08